References
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Loadman, P. Anticancer drug development. Br. J. Cancer 86, 1665–1666 (2002).
Gilman, A. & Philips, F. S. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 103, 409–436 (1946).
Heidelberger, C. et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179, 663–666 (1957).
Norris, R. E. & Adamson, P. C. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. Cancer Chemother. Pharmacol. 65, 1125–1130 (2010).
Rosenberg, B., Van Camp, L. & Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698–699 (1965).
Rowinsky, E. K. & Donehower, R. C. Pacl*taxel (taxol). N. Engl. J. Med. 332, 1004–1014 (1995).
Lindley, C. et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 7, 59–65 (1999).
Strebhardt, K. & Ullrich, A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473–480 (2008).
Iqbal, N. & Iqbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol. Biol. Int. 2014, 852748 (2014).
Prevodnik, V. K., Lavrenčak, J., Horvat, M. & Novakovič, B. J. The predictive significance of CD20 expression in B-cell lymphomas. Diagn. Pathol. 6, 1–6 (2011).
Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Ferrara, N., Hillan, K. J. & Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328–335 (2005).
McKeage, K. & Perry, C. M. Trastuzumab. Drugs 62, 209–243 (2002).
Plosker, G. L. & Figgitt, D. P. Rituximab. Drugs 63, 803–843 (2003).
Blick, S. K. & Scott, L. J. Cetuximab. Drugs 67, 2585–2607 (2007).
Shefet-Carasso, L. & Benhar, I. Antibody-targeted drugs and drug resistance—challenges and solutions. Drug Resist. Updat. 18, 36–46 (2015).
Sievers, E. L. & Senter, P. D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15–29 (2013).
Lambert, J. M. & Berkenblit, A. Antibody–drug conjugates for cancer treatment. Annu. Rev. Med. 69, 191–207 (2018).
Norsworthy, K. J. et al. FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33‐positive acute myeloid leukemia. Oncologist 23, 1103 (2018).
Ethan Ennals For The Mail On Sunday. New breed of drug which reduces bladder cancer deaths could replace chemotherapy in other cases. At dailymail.co.uk (2021).
Damelin, M., Zhong, W., Myers, J. & Sapra, P. Evolving strategies for target selection for antibody-drug conjugates. Pharm. Res. 32, 3494–3507 (2015).
Diamantis, N. & Banerji, U. Antibody-drug conjugates—an emerging class of cancer treatment. Br. J. Cancer 114, 362–367 (2016).
Ritchie, M., Tchistiakova, L. & Scott, N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 5, 13–21 (2013).
Donaghy, H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 8, 659–671 (2016).
Beck, A., Goetsch, L., Dumontet, C. & Corvaïa, N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2020).
Rummel, S. et al. Genomic (in) stability of the breast tumor microenvironment. Mol. Cancer Res. 10, 1526–1531 (2012).
De Cecco, M., Galbraith, D. N. & McDermott, L. L. What makes a good antibody-drug conjugate? Expert Opin. Biol. Ther. 21, 1–7 (2021).
Hock, M. B., Thudium, K. E., Carrasco-Triguero, M. & Schwabe, N. F. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 17, 35–43 (2015).
Abdollahpour‐Alitappeh, M. et al. Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J. Cell. Physiol. 234, 5628–5642 (2019).
Natsume, A., Niwa, R. & Satoh, M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Devel. Ther. 3, 7 (2009).
Stapleton, N. M. et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat. Commun. 2, 1–9 (2011).
Zhang, J. et al. Structural changes and aggregation mechanisms of two different dimers of an IgG2 monoclonal antibody. Biochemistry 57, 5466–5479 (2018).
Spiess, C. et al. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J. Biol. Chem. 288, 26583–26593 (2013).
Rispens, T., Ooijevaar-de Heer, P., Bende, O. & Aalberse, R. C. Mechanism of immunoglobulin G4 Fab-arm exchange. J. Am. Chem. Soc. 133, 10302–10311 (2011).
Xu, S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm. Res. 32, 3577–3583 (2015).
Singh, A. P. et al. Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation. AAPS J. 22, 1–13 (2020).
Tsumura, R. et al. Influence of the dissociation rate constant on the intra-tumor distribution of antibody-drug conjugate against tissue factor. J. Control. Release 284, 49–56 (2018).
Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).
Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody–drug conjugates. Chem. Soc. Rev. 48, 4361–4374 (2019).
Nolting, B. Linker technologies for antibody-drug conjugates. Methods Mol. Biol. 1045, 71–100 (2013).
Flygare, J. A., Pillow, T. H. & Aristoff, P. Antibody‐drug conjugates for the treatment of cancer. Chem. Biol. Drug Des. 81, 113–121 (2013).
Zhang, D. et al. Catalytic cleavage of disulfide bonds in small molecules and linkers of antibody–drug conjugates. Drug Metab. Disposition 47, 1156–1163 (2019).
Pallardó, F. V., Markovic, J., García, J. L. & Viña, J. Role of nuclear glutathione as a key regulator of cell proliferation. Mol. Asp. Med. 30, 77–85 (2009).
Estrela, J. M., Ortega, A. & Obrador, E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43, 143–181 (2006).
Doronina, S. O. et al. Novel peptide linkers for highly potent antibody− auristatin conjugate. Bioconjug. Chem. 19, 1960–1963 (2008).
Gondi, C. S. & Rao, J. S. Cathepsin B as a cancer target. Expert Opin. Ther. Targets 17, 281–291 (2013).
Dubowchik, G. M. et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug. Chem. 13, 855–869 (2002).
Jeffrey, S. C. et al. Minor groove binder antibody conjugates employing a water soluble β-glucuronide linker. Bioorg. Med. Chem. Lett. 17, 2278–2280 (2007).
Kovtun, Y. V. et al. Antibody-drug conjugates designed to eradicate tumors with hom*ogeneous and heterogeneous expression of the target antigen. Cancer Res. 66, 3214–3221 (2006).
Oflazoglu, E. et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res. 14, 6171–6180 (2008).
Erickson, H. K. et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody− maytansinoid conjugates. Bioconjug. Chem. 21, 84–92 (2010).
Girish, S. et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69, 1229–1240 (2012).
Phillips, G. D. L. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res. 68, 9280–9290 (2008).
Zhao, P. et al. Recent advances of antibody drug conjugates for clinical applications. Acta Pharm. Sin. B 10, 1589–1600 (2020).
Birrer, M. J., Moore, K. N., Betella, I. & Bates, R. C. Antibody-drug conjugate-based therapeutics: state of the science. J. Natl Cancer Inst. 111, 538–549 (2019).
Yang, H., Ganguly, A. & Cabral, F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J. Biol. Chem. 285, 32242–32250 (2010).
Kaur, R. et al. Recent developments in tubulin polymerization inhibitors: an overview. Eur. J. Med. Chem. 87, 89–124 (2014).
Walczak, C. E. Microtubule dynamics and tubulin interacting proteins. Curr. Opin. Cell Biol. 12, 52–56 (2000).
Koga, Y. et al. Antitumor effect of antitissue factor antibody‐MMAE conjugate in human pancreatic tumor xenografts. Int. J. Cancer 137, 1457–1466 (2015).
Yao, X. et al. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity. Breast Cancer Res. Treat. 153, 123–133 (2015).
Lopus, M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett. 307, 113–118 (2011).
Sandmann, A., Sasse, F. & Müller, R. Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity. Chem. Biol. 11, 1071–1079 (2004).
Morris, M. et al. Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC). Ann. Oncol. 28, v273 (2017).
Cheung-Ong, K., Giaever, G. & Nislow, C. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem. Biol. 20, 648–659 (2013).
Elmroth, K. et al. Cleavage of cellular DNA by calicheamicin γ1. DNA Repair 2, 363–374 (2003).
Boger, D. L. The duocarmycins: synthetic and mechanistic studies. Acc. Chem. Res. 28, 20–29 (1995).
Pommier, Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem. Rev. 109, 2894–2902 (2009).
Gregson, S. J. et al. Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity. J. Med. Chem. 44, 737–748 (2001).
Zein, N., Sinha, A. M., McGahren, W. J. & Ellestad, G. A. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240, 1198–1201 (1988).
Takahashi, I. et al. Duocarmycin A, a new antitumor antibiotic from Streptomyces. J. Antibiot. 41, 1915–1917 (1988).
Kawato, Y. et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187–4191 (1991).
Meddahi, A. et al. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int. J. Biol. Macromol. 18, 141–145 (1996).
Gregson, S. J. et al. Pyrrolobenzodiazepine dimer antibody–drug conjugates: synthesis and evaluation of noncleavable drug-linkers. J. Med. Chem. 60, 9490–9507 (2017).
Kamal, A. et al. Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity. J. Med. Chem. 45, 4679–4688 (2002).
Lee, A. Loncastuximab tesirine: first approval. Drugs 81, 1229–1233 (2021).
Ackerman, S. E. et al. Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity. Nat. Cancer 2, 18–33 (2021).
Qian, C. & Prieto, J. Gene therapy of cancer: induction of anti-tumor immunity. Cell. Mol. Immunol. 1, 105–111 (2004).
He, L. et al. Immune modulating antibody–drug conjugate (IM-ADC) for cancer immunotherapy. J. Med. Chem. 64, 15716–15726 (2021).
Bukhalid, R. A. et al. Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines. Cancer Res. 80, abstract 6706 (2020).
Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145 (2001).
Dumbrava, E. I. et al. Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. Cancer Res. 81, OT-03-02 (2021).
Metz, H. et al. SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist. J. Clin. Oncol. 38, 3110–3110 (2020).
Shi, F. et al. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response. Mol. Cell Biochem. 476, 1015–1024 (2021).
Amouzegar, A. et al. STING agonists as cancer therapeutics. Cancers (Basel) 13, 2695 (2021).
Duvall, J. R. et al. XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity. Cancer Res. 81, 1738–1738 (2021).
Mallet, W. et al. 784 BDC-2034: discovery of a CEA-targeting immune-stimulating antibody conjugate (ISAC) for solid tumors. J. Immunother. Cancer 9, 784–784 (2021).
Sharma, M. et al. 164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Ann. Oncol. 32, S1453–S1454 (2021).
Brun, M.-P. & Gauzy-Lazo, L. Protocols for lysine conjugation. Methods Mol. Biol. 1045, 173–187 (2013).
Matsuda, Y. & Mendelsohn, B. A. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology. Expert Opin. Biol. Ther. 21, 963–975 (2021).
f*ckunaga, A. et al. Improvement of antibody affinity by introduction of basic amino acid residues into the framework region. Biochem. Biophys. Rep. 15, 81–85 (2018).
Hagihara, Y. & Saerens, D. Engineering disulfide bonds within an antibody. BBA-Proteins Proteom. 1844, 2016–2023 (2014).
Gordon, M. R. et al. Field guide to challenges and opportunities in antibody–drug conjugates for chemists. Bioconjug. Chem. 26, 2198–2215 (2015).
Nadkarni, D. V. Conjugations to endogenous cysteine residues. Methods Mol. Biol. 2078, 37–49 (2020).
Levengood, M. R. et al. Orthogonal cysteine protection enables hom*ogeneous multi‐drug antibody–drug conjugates. Angew. Chem. Int. Ed. 56, 733–737 (2017).
Strop, P. et al. Location matters: site of conjugation modulates stability and pharmaco*kinetics of antibody drug conjugates. Chem. Biol. 20, 161–167 (2013).
Shen, B.-Q. et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30, 184–189 (2012).
Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925–932 (2008).
Junutula, J. R. et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2–positive breast cancer. Clin. Cancer Res. 16, 4769–4778 (2010).
Kung Sutherland, M. S. et al. SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122, 1455–1463 (2013).
Liberatore, F. A. et al. Site-directed chemical modification and crosslinking of a monoclonal antibody using equilibrium transfer alkylating crosslink reagents. Bioconjug. Chem. 1, 36–50 (1990).
Smith, M. E. et al. Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J. Am. Chem. Soc. 132, 1960–1965 (2010).
Chudasama, V. et al. Bromopyridazinedione-mediated protein and peptide bioconjugation. Chem. Commun. 47, 8781–8783 (2011).
Schumacher, F. F. et al. Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging. Org. Biomol. Chem. 12, 7261–7269 (2014).
Morais, M., Forte, N., Chudasama, V. & Baker, J. R. Application of next-generation maleimides (NGMs) to site-selective antibody conjugation. Bioconjugation. 2033, 15–24 (2019).
Forte, N., Chudasama, V. & Baker, J. R. hom*ogeneous antibody-drug conjugates via site-selective disulfide bridging. Drug Discov. Today.: Technol. 30, 11–20 (2018).
Hallam, T. J., Wold, E., Wahl, A. & Smider, V. V. Antibody conjugates with unnatural amino acids. Mol. Pharm. 12, 1848–1862 (2015).
Zhou, Q. Site-specific antibody conjugation for ADC and beyond. Biomedicines 5, 64 (2017).
Hallam, T. J. & Smider, V. V. Unnatural amino acids in novel antibody conjugates. Future Med. Chem. 6, 1309–1324 (2014).
Rao, C., Rangan, V. S. & Deshpande, S. Challenges in antibody–drug conjugate discovery: a bioconjugation and analytical perspective. Bioanalysis 7, 1561–1564 (2015).
Kim, E. G. & Kim, K. M. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomol. Ther. 23, 493 (2015).
Agarwal, P. & Bertozzi, C. R. Site-specific antibody–drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development. Bioconjug. Chem. 26, 176–192 (2015).
Subedi, G. P. & Barb, A. W. The structural role of antibody N-glycosylation in receptor interactions. Structure 23, 1573–1583 (2015).
Walsh, S. J. et al. Site-selective modification strategies in antibody–drug conjugates. Chem. Soc. Rev. 50, 1305–1353 (2021).
Cao, Y. J. et al. Synthesis of precision antibody conjugates using proximity-induced chemistry. Theranostics 11, 9107 (2021).
Adair, J. R. et al. Antibody–drug conjugates–a perfect synergy. Expert Opin. Biol. Ther. 12, 1191–1206 (2012).
Staudacher, A. H. & Brown, M. P. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br. J. Cancer 117, 1736–1742 (2017).
Tai, Y.-T. et al. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128–3138 (2014).
Radocha, J., van de Donk, N. W. & Weisel, K. Monoclonal antibodies and antibody drug conjugates in multiple myeloma. Cancers (Basel) 13, 1571 (2021).
Oostra, D. R. & Macrae, E. R. Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer. Breast Cancer (Lond.) 6, 103 (2014).
Dosio, F., Brusa, P. & Cattel, L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 3, 848–883 (2011).
Chari, R. V. Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv. Drug Del. Rev. 31, 89–104 (1998).
McGavin, J. K. & Spencer, C. M. Gemtuzumab ozogamicin. Drugs 61, 1317–1322 (2001).
Lamb, Y. N. Inotuzumab ozogamicin: first global approval. Drugs 77, 1603–1610 (2017).
Hinman, L. M. et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 53, 3336–3342 (1993).
Kaytor, M. D., Wilkinson, K. D. & Warren, S. T. Modulating huntingtin half‐life alters polyglutamine‐dependent aggregate formation and cell toxicity. J. Neurochem. 89, 962–973 (2004).
Siegel, M. M. et al. Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal. Chem. 69, 2716–2726 (1997).
Lucas, A. T. et al. Factors affecting the pharmacology of antibody–drug conjugates. Antibodies 7, 10 (2018).
Strop, P. et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat. Biotechnol. 33, 694–696 (2015).
Kamath, A. V. & Iyer, S. Preclinical pharmaco*kinetic considerations for the development of antibody drug conjugates. Pharm. Res. 32, 3470–3479 (2015).
Katz, J., Janik, J. E. & Younes, A. Brentuximab vedotin (SGN-35). Clin. Cancer Res. 17, 6428–6436 (2011).
Lambert, J. M. & Chari, R. V. Ado-trastuzumab Emtansine (T-DM1): an antibody–drug conjugate (ADC) for HER2-positive breast cancer. J. Medicinal Chem. 57, 6949–6964 (2014).
Tsuchikama, K. & An, Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9, 33–46 (2018).
Sun, X. et al. Effects of drug–antibody ratio on pharmaco*kinetics, biodistribution, efficacy, and tolerability of antibody–maytansinoid conjugates. Bioconjug. Chem. 28, 1371–1381 (2017).
Lyon, R. P. et al. Reducing hydrophobicity of hom*ogeneous antibody-drug conjugates improves pharmaco*kinetics and therapeutic index. Nat. Biotechnol. 33, 733–735 (2015).
Burke, P. J. et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody–drug conjugates. Mol. Cancer Ther. 16, 116–123 (2017).
Hoffmann, R. M. et al. Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). Oncoimmunology 7, e1395127 (2018).
Jäger, S. et al. Generation and biological evaluation of Fc antigen binding fragment-drug conjugates as a novel antibody-based format for targeted drug delivery. Bioconjug. Chem. 32, 1699–1710 (2021).
Yurkovetskiy, A. V. et al. A polymer-based antibody–vinca drug conjugate platform: characterization and preclinical efficacy. Cancer Res. 75, 3365–3372 (2015).
Bodyak, N. et al. Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species. Cancer Res. 75, 641–641 (2015).
Simmons, J. K. et al. Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation. Toxicol. Appl. Pharmacol. 392, 114932 (2020).
Shao, T. et al. Construction of pacl*taxel-based antibody–drug conjugates with a PEGylated linker to achieve superior therapeutic index. Signal Transduct. Target. Ther. 5, 1–3 (2020).
Buecheler, J. W. et al. Impact of payload hydrophobicity on the stability of antibody–drug conjugates. Mol. Pharm. 15, 2656–2664 (2018).
Bross, P. F. et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490–1496 (2001).
Guglielmi, C. et al. Immunophenotype of adult and childhood acute promyelocytic leukaemia: correlation with morphology, type of PML gene breakpoint and clinical outcome. A cooperative Italian study on 196 cases. Br. J. Haematol. 102, 1035–1041 (1998).
Parigger, J., Zwaan, C., Reinhardt, D. & Kaspers, G. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia. Expert Rev. Anticancer Ther. 16, 137–146 (2016).
Petersdorf, S. et al. Preliminary results of Southwest Oncology Group study S0106: An international intergroup phase 3 randomized trial comparing the addition of Gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation Gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114, 790 (2009).
Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508–1516 (2012).
Amadori, S. et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial. J. Clin. Oncol. 34, 972–979 (2016).
Burnett, A. K. et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29, 369–377 (2011).
Hills, R. K. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15, 986–996 (2014).
Lamba, J. K. et al. CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children’s Oncology Group trial AAML0531. J. Clin. Oncol. 35, 2674 (2017).
Younes, A., Yasothan, U. & Kirkpatrick, P. Brentuximab vedotin. Nat. Rev. Drug Discov. 11, 19 (2012).
Hamblett, K. J. et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies. Blood 106, 610 (2005).
Best, R. L. et al. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy. Toxicol. Appl. Pharmacol. 421, 115534 (2021).
Bartlett, N. L. et al. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas. Blood 122, 848–848 (2013).
Pro, B. et al. Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 122, 1809–1809 (2013).
Chen, R. et al. Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J. Clin. Oncol. 29, 8031–8031 (2011).
Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 30, 2183 (2012).
Pro, B. et al. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J. Clin. Oncol. 29, 8032–8032 (2011).
Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190–2196 (2012).
Horwitz, S. M. et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 5, 5098–5106 (2021).
Richardson, N. C. et al. FDA approval summary: brentuximab vedotin in first‐line treatment of peripheral T‐Cell lymphoma. Oncologist 24, e180 (2019).
Straus, D. J. et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 8, e410–e421 (2021).
Shah, N. N. et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr. Blood Cancer 62, 964–969 (2015).
Lanza, F. et al. CD22 expression in b-cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults. Cancers (Basel) 12, 303 (2020).
Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study. Cancer 125, 2474–2487 (2019).
Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).
Turner, A. & Kjeldsberg, C. R. Hairy cell leukemia: a review. Medicine 57, 477–499 (1978).
Kreitman, R. J. & Pastan, I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res. 17, 6398–6405 (2011).
Cordone, I. et al. Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia. J. Clin. Pathol. 48, 955–960 (1995).
Babuŝíková, O., Tomova, A., Kusenda, J. & Gyarfas, J. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment. Neoplasma 48, 350–357 (2001).
Janus, A. & Robak, T. Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin. Biol. Ther. 19, 501–508 (2019).
Kreitman, R. J. et al. Moxetumomab Pasudotox-Tdfk in heavily pretreated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal Phase 3 Trial. Blood 134, 2808–2808 (2019).
Kreitman, R. J. et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J. Hematol. Oncol. 14, 1–11 (2021).
Biocodex’s, G. FDA new drug approvals in Q3 2018. Nat. Rev. Drug Discov. 17, 779 (2018).
Deeks, E. D. Polatuzumab vedotin: first global approval. Drugs 79, 1467–1475 (2019).
Zheng, B. et al. In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol. Cancer Ther. 8, 2937–2946 (2009).
Pfeifer, M. et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia 29, 1578–1586 (2015).
Urquhart, L. FDA new drug approvals in Q2 2019. Nat. Rev. Drug Discov. 18, 575–576 (2019).
Sehn, L. H. et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension. Blood 136, 17–19 (2020).
Seckinger, A. et al. Target expression, generation, preclinical activity, and pharmaco*kinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31, 396–410 (2017).
Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207–221 (2020).
Jain, N. et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 4, 449–457 (2020).
Zammarchi, F. et al. ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131, 1094–1105 (2018).
Hartley, J. A. Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy. Expert Opin. Biol. Ther. 21, 931–943 (2021).
Hartley, J. A. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin. Investig. Drugs 20, 733–744 (2011).
Staben, L. R. et al. Systematic variation of pyrrolobenzodiazepine (PBD)-dimer payload physicochemical properties impacts efficacy and tolerability of the corresponding antibody–drug conjugates. J. Med. Chem. 63, 9603–9622 (2020).
Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22, 790–800 (2021).
Abraham, J. Trastuzumab emtansine in advanced HER2-positive breast cancer. Clin. Cancer Res. 13, 1648–1655 (2007).
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Junttila, T. T. et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res. Treat. 128, 347–356 (2011).
Diéras, V. et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 732–742 (2017).
Blackwell, K. L. et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J. Clin. Oncol. 30, LBA1–LBA1 (2012).
Pondé, N. et al. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer. Eur. J. Cancer 126, 65–73 (2020).
Wedam, S. et al. FDA Approval summary: ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin. Cancer Res. 26, 4180–4185 (2020).
Mamounas, E. et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann. Oncol. 32, 1005–1014 (2021).
Chang, E. et al. FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma. Clin. Cancer Res. 27, 922–927 (2021).
Challita-Eid, P. M. et al. Enfortumab vedotin antibody–drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 76, 3003–3013 (2016).
Liu, Y. et al. Role of Nectin‑4 protein in cancer. Int. J. Oncol. 59, 1–14 (2021).
Heath, E. I. & Rosenberg, J. E. The biology and rationale of targeting nectin-4 in urothelial carcinoma. Nat. Rev. Urol. 18, 93–103 (2021).
Powles, T. et al. Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. J. Clin. Oncol. 39, 393–393 (2021).
Petrylak, D. P. et al. EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). J. Clin. Oncol. 37, TPS497–TPS497 (2019).
Evan, Y. Y. et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 22, 872–882 (2021).
sh*tara, K. et al. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 24, 780–789 (2021).
Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med. 382, 610–621 (2020).
Modi, S. et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Cancer Res. 81, PD3-06. (2021).
Cortés, J. et al. LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann. Oncol. 32, S1283–S1346 (2021).
Cortés, J. et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Ann. Oncol. 32, S1287–S1288 (2021).
Tolaney, S. et al. 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Ann. Oncol. 32, S507–S508 (2021).
Li, B. T. et al. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N. Engl. J. Med. 386, 241–251 (2022).
Cottin, V. Interstitial lung disease. Eur. Respir. Rev. 22, 26–32 (2013).
Janjigian, Y. et al. 1500TiP A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03). Ann. Oncol. 31, S930–S931 (2020).
Lipinski, M., Parks, D. R., Rouse, R. V. & Herzenberg, L. A. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc. Natl Acad. Sci. 78, 5147–5150 (1981).
Rapani, E., Sacchetti, A., Corda, D. & Alberti, S. Human Trop‐2 is a tumor‐associated calcium signal transducer. Int. J. Cancer 76, 671–676 (1998).
Wang, J. et al. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol. Cancer Ther. 7, 280–285 (2008).
Zeng, P. et al. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci. Rep. 6, 1–7 (2016).
Perrone, E. et al. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Mol. Oncol. 14, 645–656 (2020).
Sahota, S. & Vahdat, L. T. Sacituzumab govitecan: an antibody–drug conjugate. Expert Opin. Biol. Ther. 17, 1027–1031 (2017).
Bardia, A. et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med. 384, 1529–1541 (2021).
Bardia, A. et al. LBA17 ASCENT: a randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann. Oncol. 31, S1149–S1150 (2020).
O’Shaughnessy, J. et al. Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC). J. Clin. Oncol. 39, 1077–1077 (2021).
Li, J., Wang, R. & Gao, J. Novel anticancer drugs approved in 2020. Drug Discov. Ther. 15, 44–47 (2021).
Kaplon, H. & Reichert, J. M. Antibodies to watch in 2021. MAbs 13, 1860476 (2021).
Kitamura, N. et al. Current trends and future prospects of molecular targeted therapy in head and neck squamous cell carcinoma. Int. J. Mol. Sci. 22, 240 (2021).
Cognetti, D. M. et al. Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC). J. Clin. Oncol. 37, 6014–6014 (2019).
Gillenwater, A. M. et al. RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial. J. Clin. Oncol. 36, 6039–6039 (2018).
Jiang, J. et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol. Lett. 324, 30–37 (2020).
Xu, Y. et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 24, 913–925 (2021).
Peng, Z. et al. A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers. J. Clin. Oncol. 38, 4560–4560 (2020).
Peng, Z. et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun. 41, 1173–1182 (2021).
Sheng, X. et al. An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009). J. Clin. Oncol. 39, 4584–4584 (2021).
Alley, S. C. et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro. Cancer Res. 79, 221–221 (2019).
Liu, Y. et al. Tissue factor–activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res. 71, 6492–6502 (2011).
Coleman, R. L. et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 22, 609–619 (2021).
De Bono, J. S. et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial. Lancet Oncol. 20, 383–393 (2019).
Ab, O. et al. IMGN853, a folate receptor-α (FRα)–targeting antibody–drug conjugate, exhibits potent targeted antitumor activity against FRα-expressing tumors. Mol. Cancer Ther. 14, 1605–1613 (2015).
Moore, K. N. et al. FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer. J. Clin. Oncol. 35, TPS5607–TPS5607 (2017).
Moore, K. et al. FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann. Oncol. 30, v403 (2019).
Moore, K. N. et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J. Clin. Oncol. 35, 1112 (2017).
O’Malley, D. M. et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol. Oncol. 157, 379–385 (2020).
O’Malley, D. M. et al. Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis. J. Clin. Oncol. 39, 5504–5504 (2021).
Okajima, D. et al. Datopotamab deruxtecan, a novel TROP2-directed antibody–drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol. Cancer Ther. 20, 2329–2340 (2021).
Spira, A. et al. OA03. 03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. J. Thorac. Oncol. 16, S106–S107 (2021).
Shimizu, T. et al. O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study. Ann. Oncol. 32, S285 (2021).
Yoh, K. et al. A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01). J. Clin. Oncol. 39, TPS9127–TPS9127 (2021).
Zhang, X. et al. CEACAM5 stimulates the progression of non-small-cell lung cancer by promoting cell proliferation and migration. J. Int. Med. Res. 48, 0300060520959478 (2020).
Decary, S. et al. Preclinical activity of SAR408701: a novel anti-CEACAM5–maytansinoid antibody–drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin. Cancer Res. 26, 6589–6599 (2020).
Gazzah, A. et al. Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). J. Clin. Oncol. 38, 9505–9505 (2020).
Guo, J. et al. Characterization and higher-order structure assessment of an interchain cysteine-based ADC: impact of drug loading and distribution on the mechanism of aggregation. Bioconjug. Chem. 27, 604–615 (2016).
Malik, P., Phipps, C., Edginton, A. & Blay, J. Pharmaco*kinetic considerations for antibody-drug conjugates against cancer. Pharm. Res. 34, 2579–2595 (2017).
Hamblett, K. J. et al. Altering antibody–drug conjugate binding to the neonatal Fc receptor impacts efficacy and tolerability. Mol. Pharm. 13, 2387–2396 (2016).
Mahalingaiah, P. K. et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol. Ther. 200, 110–125 (2019).
Khera, E. & Thurber, G. M. Pharmaco*kinetic and immunological considerations for expanding the therapeutic window of next-generation antibody–drug conjugates. Biodrugs 32, 465–480 (2018).
Mecklenburg, L. A brief introduction to antibody–drug conjugates for toxicologic pathologists. Toxicol. Pathol. 46, 746–752 (2018).
Hackshaw, M. D. et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. 183, 23–39 (2020).
Powell, C. et al. 289P Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies. Ann. Oncol. 31, S357–S358 (2020).
Tarantino, P. et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 7, 1873–1881 (2021).
Spira, A. et al. OA03.03 Datopotamab deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. J. Thorac. Oncol. 16, S106–S107 (2021).
Jin, Y. et al. Stepping forward in antibody-drug conjugate development. Pharmacol. Ther. 229, 107917 (2021).
Tumey, L. N. An Overview of the Current ADC Discovery Landscape. Antibody-Drug Conjugates 2078, 1–22 (2020).
Singh, A. P. & Shah, D. K. A “dual” cell-level systems PK-PD model to characterize the bystander effect of ADC. J. Pharm. Sci. 108, 2465–2475 (2019).
Wu, S.-G. & Shih, J.-Y. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer. Mol. Cancer 17, 1–14 (2018).
Loganzo, F., Sung, M. & Gerber, H.-P. Mechanisms of resistance to antibody–drug conjugates. Mol. Cancer Ther. 15, 2825–2834 (2016).
Irie, H. et al. Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728. Cancer Sci. 111, 2123 (2020).
Sipos, G. & Kuchler, K. Fungal ATP-binding cassette (ABC) transporters in drug resistance & detoxification. Curr. Drug Targets 7, 471–481 (2006).
Buongervino, S. N. et al. Antibody-drug conjugate efficacy in neuroblastoma-role of payload, resistance mechanisms, target density, and antibody internalization. Mol. Cancer Ther. 20, 2228–22239 (2021).
Lee, Y. T., Tan, Y. J. & Oon, C. E. Molecular targeted therapy: treating cancer with specificity. Eur. J. Pharmacol. 834, 188–196 (2018).
Andreev, J. et al. Bispecific antibodies and antibody–drug conjugates (ADCs) bridging HER2 and prolactin receptor improve efficacy of HER2 ADCs. Mol. Cancer Ther. 16, 681–693 (2017).
de Goeij, B. E. et al. Efficient payload delivery by a bispecific antibody–drug conjugate targeting HER2 and CD63. Mol. Cancer Ther. 15, 2688–2697 (2016).
Tang, F. et al. One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody–drug conjugates. Org. Biomol. Chem. 14, 9501–9518 (2016).
Yamazaki, C. M. et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 1–13 (2021).
Whalen, K. A. et al. Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer. Mol. Cancer Ther. 18, 1926–1936 (2019).
Dal Corso, A. et al. A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo. J. Control. Release 264, 211–218 (2017).
Tolcher, A. W. et al. A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. J. Clin. Oncol. 39, 3015–3015 (2021).
